Last reviewed · How we verify
GB002
At a glance
| Generic name | GB002 |
|---|---|
| Also known as | PK10571 |
| Sponsor | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (PHASE3)
- Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) (PHASE3)
- Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) (PHASE3)
- Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy Subjects (PHASE1)
- GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension (PHASE1)
- Phase 1A Safety Trial of Inhaled PK10571 (GB002) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB002 CI brief — competitive landscape report
- GB002 updates RSS · CI watch RSS
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. portfolio CI